| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Janis Fricke, Claudius Lenz, Jonas Wick, Felix Blei, Dirk Hoffmeiste. Production Options for Psilocybin: Making of the Magic. Chemistry (Weinheim an der Bergstrasse, Germany). vol 25. issue 4. 2019-01-24. PMID:30011099. |
however, clinical trials have recognized psilocybin as a valuable candidate to be developed into a medication against depression and anxiety. |
2019-01-24 |
2023-08-13 |
Not clear |
| J B Stroud, T P Freeman, R Leech, C Hindocha, W Lawn, D J Nutt, H V Curran, R L Carhart-Harri. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology. vol 235. issue 2. 2018-12-31. PMID:29085980. |
psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. |
2018-12-31 |
2023-08-13 |
Not clear |
| R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling, J A Rickard, B Forbes, A Feilding, D Taylor, H V Curran, D J Nut. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. vol 235. issue 2. 2018-12-31. PMID:29119217. |
psilocybin with psychological support for treatment-resistant depression: six-month follow-up. |
2018-12-31 |
2023-08-13 |
Not clear |
| Andy Whelan, Mark I Johnso. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? Pain management. vol 8. issue 3. 2018-10-24. PMID:29722608. |
tentative evidence from a systematic review suggests that lsd (7 studies, 323 participants) and psilocybin (3 studies, 92 participants) may be beneficial for depression and anxiety associated with distress in life-threatening diseases. |
2018-10-24 |
2023-08-13 |
human |
| Michael P Bogenschutz, Stephen Ros. Therapeutic Applications of Classic Hallucinogens. Current topics in behavioral neurosciences. vol 36. 2018-09-20. PMID:28512684. |
to provide a clinical perspective, case summaries are provided of two individuals who received treatment in recent controlled trials of psilocybin: one being treated for alcoholism, the other suffering from anxiety and depression related to fear of death due to a cancer diagnosis. |
2018-09-20 |
2023-08-13 |
human |
| Rafael G Dos Santos, José Carlos Bouso, Miguel Ángel Alcázar-Córcoles, Jaime E C Halla. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert review of clinical pharmacology. vol 11. issue 9. 2018-09-17. PMID:30102078. |
expert commentary: psilocybin and lsd reduced anxiety and depression in cancer patients and symptoms of alcohol and tobacco dependence, and ayahuasca reduced depression symptoms in treatment-resistant depression. |
2018-09-17 |
2023-08-13 |
Not clear |
| Facundo Carrillo, Mariano Sigman, Diego Fernández Slezak, Philip Ashton, Lily Fitzgerald, Jack Stroud, David J Nutt, Robin L Carhart-Harri. Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. Journal of affective disorders. vol 230. 2018-09-04. PMID:29407543. |
natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. |
2018-09-04 |
2023-08-13 |
Not clear |
| John D McCorvy, Reid Hj Olsen, Bryan L Rot. Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2018-08-24. PMID:27909171. |
psilocybin for depression and anxiety associated with life-threatening illnesses. |
2018-08-24 |
2023-08-13 |
Not clear |
| Randall T Brown, Christopher R Nicholas, Nicholas V Cozzi, Michele C Gassman, Karen M Cooper, Daniel Muller, Chantelle D Thomas, Scott J Hetzel, Kelsey M Henriquez, Alexandra S Ribaudo, Paul R Hutso. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clinical pharmacokinetics. vol 56. issue 12. 2018-06-28. PMID:28353056. |
psilocybin is a psychedelic tryptamine that has shown promise in recent clinical trials for the treatment of depression and substance use disorders. |
2018-06-28 |
2023-08-13 |
Not clear |
| Robin L Carhart-Harris, Guy M Goodwi. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443617. |
in this circumspective piece, rlc-h and gmg share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression. |
2018-05-16 |
2023-08-13 |
human |
| David Nut. Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2018-01-31. PMID:27909163. |
psilocybin for anxiety and depression in cancer care? |
2018-01-31 |
2023-08-13 |
Not clear |
| Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L Schmid. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909164. |
rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. |
2017-12-27 |
2023-08-13 |
Not clear |
| Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, Brian L Schmid. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909164. |
historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. |
2017-12-27 |
2023-08-13 |
Not clear |
| Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedins. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909165. |
psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. |
2017-12-27 |
2023-08-13 |
human |
| Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedins. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909165. |
previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. |
2017-12-27 |
2023-08-13 |
human |
| Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedins. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England). vol 30. issue 12. 2017-12-27. PMID:27909165. |
the effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. |
2017-12-27 |
2023-08-13 |
human |
| Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H Curran, David J Nut. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The lancet. Psychiatry. vol 3. issue 7. 2017-11-08. PMID:27210031. |
psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. |
2017-11-08 |
2023-08-13 |
Not clear |
| Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H Curran, David J Nut. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The lancet. Psychiatry. vol 3. issue 7. 2017-11-08. PMID:27210031. |
here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression. |
2017-11-08 |
2023-08-13 |
Not clear |
| Suravi Patr. Return of the psychedelics: Psilocybin for treatment resistant depression. Asian journal of psychiatry. vol 24. 2017-02-14. PMID:27931907. |
return of the psychedelics: psilocybin for treatment resistant depression. |
2017-02-14 |
2023-08-13 |
Not clear |
| Suravi Patr. Return of the psychedelics: Psilocybin for treatment resistant depression. Asian journal of psychiatry. vol 24. 2017-02-14. PMID:27931907. |
psilocybin, the clinically most researched classic psychedelic has recently been tested for its safety and efficacy in a clinical population of treatment resistant depression. |
2017-02-14 |
2023-08-13 |
Not clear |